Physicians' Academy for Cardiovascular Education

AHA 2021

PACE-CME.org reports news from the virtual AHA Scientific Sessions 2021. Find coverage of the latest CV news on PACE-CME.

FXIa inhibitor as a promising new anticoagulant drug

3' education - Nov. 23, 2021 - Prof. Jeffrey Weitz, MD
Milvexian is a new oral FXIa inhibitor and has been examined for thromboprophylaxis in patients after knee replacement. Prof. Weitz shares the results of a phase 2 study.

AHA 2021 Milvexian is a new oral FXIa inhibitor and has been examined for thromboprophylaxis in patients after knee replacement. Prof. Weitz shares the results of a phase 2 study.

Reversal of antiplatelet effects of P2Y12i by monoclonal antibody fragment

News - Nov. 22, 2021

AHA 2021 An interim analysis of the REVERSE-IT study showed that administration of bentracimab resulted in immediate and sustained reversal of antiplatelet effect of ticagrelor in patients who present with uncontrolled major or life-threating bleeding or who require urgent surgery or invasive procedures.

Digital transformation in cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD
Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage
 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD
Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19. patiënten met COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

No improvement of dementia outcomes with aspirin in T2DM patients

News - Nov. 16, 2021

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

Oral PCSK9 inhibitor effectively lowers LDL-c

News - Nov. 16, 2021

AHA 2021 Two phase I studies report the safety and effectiveness of MK-0616, a new oral PCSK9 inhibitor. MK-0616 lowered free PCSK9 in the blood by ≥90% and reduced LDL-c by ~65% after 14 days of treatment, compared to baseline.

Highly-purified EPA does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

SGLT2i improves symptoms in HF

News - Nov. 15, 2021

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

Rigorous assessment of effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD
In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

Testing individual triggers for AF in n-of-1 trials

News - Nov. 15, 2021

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.

Transendocardial delivery of mesenchymal precursor cells in chronic HFrEF

News - Nov. 15, 2021

AHA 2021 This randomized, sham-controlled study showed that mesenchymal precursor cells did not reduce recurrent decompensated HF events. However, non-fatal MI or non-fatal stroke and decreased cardiac death were reduced in specific subgroups.

AHA 2021